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        A long-standing but poorly understood obser-
vation in stem cell biology is that the quiescence 
of the adult stem cells associates with their long-
term functions (  1  –  6  ). The molecular pathway 
that keeps them in quiescence is largely ob-
scure, although recent studies have implicated 
stem cell niches (  4  ) and cell-intrinsic functions 
of   p21   (  5  ) and   Pten   (  6  ) in this process. The sig-
nifi  cance of quiescence in stem cell function is 
bolstered as genetic disruption of its quiescence 
almost invariably inactivates the hematopoietic 
stem cell (HSC) function (  4  –  6  ). Nevertheless, 
it is largely unclear how an active metabolism is 
incompatible with a normal HSC function. 
  In addition to cell-intrinsic factors, accu-
mulating data demonstrated that residence of 
adult HSCs in the BM niches is essential for 
their quiescence and long-term functions (  7  –  9  ). 
Because exposure to high levels of oxygen dam-
ages the functions of HSCs (  10  –  15  ), it has been 
proposed that hypoxia is important for HSC 
functions. However, the underlying molecular 
mechanism of how hypoxia maintains the stem-
ness is unknown. 
  In   Drosophila   and in vitro  –  cultured mam-
malian cells, hypoxia activates tuberous sclero-
sis complex (TSC), which can inhibit the target 
of rapamycin (TOR), through REDD1 and 
AMP-activated protein kinase ( 16  –  20  ). Whether 
this pathway operates in the HSCs has yet to 
be tested. 
  The mammalian TOR (mTOR) pathway 
has emerged as a key regulator for cellular me-
tabolism. Accumulating data have demonstrated 
that mTOR regulates several important cellu-
lar functions, including protein synthesis, au-
tophagy, endocytosis and nutrient uptake (  21  ). 
An increased mTOR activity results in increased 
cellular growth and nonmalignant growth of 
cells in solid organs (  22, 23  ). Recently, it has 
been demonstrated that mTOR controls the 
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  The tuberous sclerosis complex (TSC)  –  mammalian target of rapamycin (mTOR) pathway is 
a key regulator of cellular metabolism. We used conditional deletion of   Tsc1   to address 
how quiescence is associated with the function of hematopoietic stem cells (HSCs). We 
demonstrate that   Tsc1   deletion in the HSCs drives them from quiescence into rapid cy-
cling, with increased mitochondrial biogenesis and elevated levels of reactive oxygen 
species (ROS). Importantly, this deletion dramatically reduced both hematopoiesis and 
self-renewal of HSCs, as revealed by serial and competitive bone marrow transplantation. 
In vivo treatment with an ROS antagonist restored HSC numbers and functions. These data 
demonstrated that the TSC  –  mTOR pathway maintains the quiescence and function of 
HSCs by repressing ROS production. The detrimental effect of up-regulated ROS in meta-
bolically active HSCs may explain the well-documented association between quiescence 
and the   “  stemness  ”   of HSCs. 
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    Figure 1.         Loss of Tsc1 drives HSCs from quiescence to rapid proliferation and results in increased frequency and number of HSCs.   (a)   Tsc1   is 
effi  ciently deleted in LT-HSCs. The 6-wk-old   Tsc1  fl  /fl   mx-1-cre +    mice and the   Tsc1  fl  /fl   mx-1-cre       littermates were treated with pIpC for 2 wk. At 10 d after 
completion of pIpC treatments, LT-HSCs, as defi  ned by the FLSKCD48        phenotype, were sorted by FACS. mRNA levels were tested by real-time RT-PCR. 
Data shown have been normalized to HPRT. Data shown are means   ±   SD of results from fi  ve independent experiments. (b) The pS6 level is up-regulated in 
Tsc1-defi  cient LT-HSCs measured by fl  ow cytometry. The x axis shows the intensity of pS6 staining, and the y axis shows the cell number. (left) Represen-
tative FACS profi  les. (right) Means   ±   SD (  n   = 3) of mean fl  uorescence. The mean fl  uorescence intensity (MFI) is increased by     10-fold in the Tsc1-defi  -
cient HSCs. (c) RNA/DNA contents of the Ctrl and   Tsc1  fl  /fl   mx-1-cre +    HSCs.   Tsc1  fl  /fl   mx-1-cre +    HSCs are less quiescent than the   Tsc1  fl  /fl   mx-1-cre        littermates, JEM VOL. 205, September 29, 2008 
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as measured by pyronin Y (RNA contents) and HOECHST (DNA contents) staining. (left) Dot plots of gated FLSKCD48        cells are shown (numbers indicate 
percentages). (right) The summary data of quiescent (percentage of pyronin Y  low   cells) and the percentage of S, M, and G2M cells (  >  2n DNA contents) 
are shown. Data shown are means   ±   SD of results from three independent experiments with a total of six mice per group. (d) Conditional deletion of 
the Tsc1 gene resulted in enhanced proliferation of the LT-HSCs. Mice were treated with pIpC as in panel a. BM cells were analyzed 24 h after BrdU 
labeling. (left) The histograms depict distributions of BrdU incorporation among the FLSKCD48        cells (numbers indicate percentages). (right) The bar 
graph shows the percentage of BrdU  +   cells among the FLSKCD48        cells. Data shown are means   ±   SD of results from three independent experiments, 
with a total of six mice per group. (e)   Tsc1- defi  cient WBM and HSCs have increased apoptosis, indicated as Annexin V  +   7AAD      . (left) Representative 
profi  les from one mouse per group are presented (numbers indicate percentages). (right) Means   ±   SD of the percentage of Annexin V  + 7AAD       cells from 
four experiments with a total of eight mice per group are shown. (f) Sustained increase in the frequency and absolute number of HSCs in the pIpC-
treated   Tsc1  fl  /fl   mx-1-cre +    BM. At 10 and 30 d after pIpC treatments, BM from   Tsc1  fl  /fl   mx-1-cre +    (KO) and   Tsc1  fl  /fl   mx-1-cre       (Ctrl) littermates were stained 
with a panel of antibodies to identify LT-HSCs and short-term HSCs (ST-HSCs). (left) Data shown are FACS profi  les depicting the increase in the fre-
quency of HSCs on day 10 after completion of the pIpC treatment (numbers indicate percentages). (right) The bar graphs summarize the sustained in-
crease in the frequency and number of HSCs on days 10 and 30 after pIpC treatment. Data shown are means   ±   SD of results from three (day 30;   n   = 6) 
or fi  ve (day 10;   n   = 10) experiments.     
 
mitochondrial oxidative function through a YY1  –  PGC-1     
transcriptional complex (  24  ). Although systemic analysis of 
the mTOR pathway in the function of HSCs has not been 
performed, several lines of evidence are consistent with a criti-
cal role for the pathway in HSC function. First, two groups 
reported that the targeted mutation of   Pten  , a negative regu-
lator of phosphoinositide 3-kinase (PI3K) and AKT, which 
are inhibitors for TSC function, reduced long-term HSC 
(LT-HSC) function (  6, 25  ). Second, up-regulated mTOR 
activity is associated with a higher level of intracellular reac-
tive oxygen species (ROS) (  26  ). Nevertheless, because these 
regulators have multiple functions, the link between the mTOR 
pathway and HSCs remains tentative. 
  TSC was fi  rst defi  ned by genetic mutations leading to 
nonmalignant growth in solid organs in patients with genetic 
lesions of two genes, now called   TSC1   and   TSC2   (  27, 28  ). 
Genetic screening in   Drosophila   demonstrated that the TSC 
determined the size of solid organs (  29, 30  ). More recently, 
TSC has emerged as the major negative regulator for the mTOR 
(  31, 32  ) (for review see reference   33  ). 
  In this paper, we demonstrate that the targeted mutation 
of   TSC1   disrupts quiescence and long-term functions of the 
HSCs. Moreover, we showed that the   Tsc1   defect leads to 
increased mitochondrion biogenesis and accumulation of ROS, 
and that the HSC defects can be largely restored by blocking 
ROS activity in vivo. Collectively, our data demonstrated that 
the TSC  –  mTOR pathway controls quiescence and functions 
of HSCs by repressing ROS production. 
    RESULTS   
  TSC1 controls quiescence of HSCs 
  To address the function of mTOR activation in the biology 
of HSCs, we generated mice that express both   MX-Cre   and 
fl  oxed   Tsc1   locus and used polyinosine-polycytidine (pIpC) 
treatment to induce deletion of TSC in the HSCs. Start-
ing at 6 wk of age, we treated the   Tsc1  fl / fl   mx-1-cre  +     and the 
  Tsc1  fl / fl   mx-1-cre          (control [Ctrl]) mice with pIpC every other 
day for 2 wk to delete the   Tsc1   gene, which is hereby referred 
to as KO in the fi  gures. The pIpC treatment almost completely 
deleted the   Tsc1   gene in the HSCs of the   Tsc1  fl / fl   mx-1-cre  +     
mice, as the   Tsc1   transcripts in Flt2       Lin       Sca-1  +  c-Kit  +   (FLSK) 
CD48        LT-HSCs (  34  ) from   Tsc1  fl / fl   mx-1-cre  +     mice were re-
duced by   >  500-fold at 10 d after the pIpC treatment (  Fig. 1 a  ).   
In normal HSCs, mTOR activity is at a low level, as shown 
by fl  ow cytometry of phosphorylated S6 (pS6), whereas in 
  Tsc1   KO HSCs, the level of pS6 is increased by     10-fold 
(  Fig. 1 b  ). These data confi  rmed that   Tsc1   is completely de-
leted and mTOR activity is signifi  cantly increased in HSCs 
of   Tsc1  fl / fl   mx-1-cre  +     mice after pIpC treatment. 
  It is proposed that one of the major functions of the hy-
poxic HSC niche is to keep HSCs quiescent and that the 
quiescence is critical to maintain the stemness (  14, 35  ). There-
fore, we tested the eff  ect of mTOR activation on stem cell 
quiescence. First, we measured the total RNA/DNA con-
tents in the LT-HSCs by pyronin/HOECHST staining. As 
shown in   Fig. 1 c  , at 10 d after pIpC treatment     70% of the 
FLSKCD48        LT-HSCs in the Ctrl mice are pyronin Y  low  , 
consistent with their quiescent status. In the pIpC-treated 
  Tsc1  fl  /fl    mx-1-cre  +     mice, only   <  15% of the LT-HSCs were py-
ronin Y  low  , which indicated that most of the LT-HSCs had 
exited the G  0   phase. Judged by DNA contents, a signifi  cant 
increase in the proportion of S- and G2M-phase cells was 
also observed. 
  Second, we measured the rate of HSC proliferation by 
BrdU incorporation, as shown in   Fig. 1 d  . At 10 d after pIpC 
treatment, nearly 60% of LT-HSCs in   Tsc1  fl  /fl    mx-1-cre  +     mice 
incorporated BrdU after 24 h of labeling, which is nearly 
fourfold as high as those from the Ctrl mice (13%). Thus, the 
data in   Fig. 1 (a  –  d)   indicated that   Tsc1   defi  ciency drives HSCs 
from quiescence to rapid cell cycle. 
  By fl  ow cytometry staining with Annexin V and 7  –  ami-
noactinomycin D, we observed that the levels of apoptosis 
among Ctrl HSCs is low (1%), as compared with that of the 
whole BM (WBM; 7%;   Fig. 1 e  ). However, the apoptosis of 
  Tsc1   KO HSCs was increased by   >  10-fold (  Fig. 1 e  ). Overall, 
signifi  cant increases in both the frequency and number of 
HSCs were observed in the pIpC-treated   Tsc1  fl  /fl    mx-1-cre  +     
mice (  Fig. 1 f  ). Therefore, the increase in proliferation ap-
peared to dominate over apoptosis. The increase of apoptosis 
may explain the reduction in the frequency and absolute num-
ber of HSCs in   Tsc1  fl  /fl    mx-1-cre  +     mice on day 30 when com-
pared with those on day 10 (  Fig. 1 f  ). 2400   M  TOR AND STEMNESS OF HEMATOPOIETIC STEM CELLS   | Chen et al. 
and erythroid cells, are also signifi  cantly reduced in the WBM 
compared with those in the Ctrl BM (  Fig. 2 c  ). 
  The BM hypocellularity could in theory be caused by in-
creased apoptosis and/or defective proliferation. To evaluate 
the rate of proliferation of WT and KO BM in vivo, we pulsed 
the WT and KO mice with BrdU on day 10 after pIpC treat-
ment and measured BrdU incorporation on total and Lin        BM 
cells 24 h after the pulse. As shown in Fig. S1 (available at http://
www.jem.org/cgi/content/full/jem.20081297/DC1), the rate 
of BrdU incorporation was similar in WT and KO BM, regard-
less of whether the WBM or Lin        cells were compared. To 
determine whether TSC1 deletion impaired the colony forma-
tion activity of progenitor cells, we compared the WT and KO 
BM for the number and types of colonies formed in a standard 
CFU assay. As shown in Table S1, an increase of total colonies, 
  Targeted mutation of TSC1 causes HSC-intrinsic defects 
in hematopoiesis 
  Interestingly, despite the increase in HSC numbers, the 
pIpC-treated   Tsc1  fl  /fl    mx-1-cre  +     mice have an     50% reduction 
in white blood cell counts (P = 0.001) at 30 d after the pIpC 
treatment, as measured by a complete blood count (CBC) 
test, most of which are contributed by reduced lymphocytes. 
The counts of monocytes and RBCs in the mutant mice ap-
peared normal (  Fig. 2 a  ).   To understand the hematopoiesis 
defects after the deletion of   Tsc1  , we analyzed a representa-
tion of multiple lineages of hematopoietic cells in the BM. 
We found that in   Tsc1  fl  /fl    mx-1-cre  +     mice, the BM cellularity is 
signifi  cantly reduced on day 10 of the pIpC treatments. The 
BM hypocellularity is more severe on day 30 (  Fig. 2 b  ). Dif-
ferentiated blood cells, such as B lymphocytes, myeloid cells, 
    Figure 2.         Conditional deletion of   Tsc1   results in abnormal hematopoiesis.   The 6-wk-old   Tsc1  fl  /fl   mx-1-cre +    mice and the   Tsc1  fl  /fl   mx-1-cre       litter-
mates were treated with pIpC, as in   Fig. 1  . (a) Reduced number of blood cells, as determined by CBC. The number in the littermate Ctrl is defi  ned as 
100%. LY, lymphocytes; MO, monocytes; NE, neutrophils and eosinophils. (b) Progressive loss of BM cellularity in the   Tsc1 -defi  cient   Tsc1  fl  /fl   mx-1-cre +   
mice. (c) Reduction of multiple lineages of differentiated leukocytes in the BM at 30 d after pIpC treatments. (d) Reduction of B lymphocytes but in-
crease of erythrocytes in the spleens of Tsc1 mutant mice at 30 d after pIpC treatments. (e) Deletion of the   Tsc1   gene caused extramedullary he-
matopoiesis in the spleen. (left) The number of FLSK48        HSCs in the spleens of   Tsc1  fl  /fl   mx-1-cre +    and Ctrl mice 10 and 30 d after pIpC treatment. Data 
shown in a  –  e are means   ±   SD of results from fi  ve experiments with a total of 10 mice per group. (middle) Hematoxylin and eosin staining of the 
spleens of   Tsc1  fl  /fl   mx-1-cre +    and Ctrl littermates. The arrows indicate the high frequency of megakaryocytes. Bars, 20   μ  m. In fi  ve higher power fi  elds, 
means of 49 and 7 megakaryocytes were found in spleen sections of   Tsc1  fl  /fl   mx-1-cre +    and Ctrl littermates, respectively (  n   = 4). (f) Radioprotection by 
the Tsc1 mutant splenic HSCs. 20   ×   10  6   spleen cells were injected into lethally irradiated recipients. The survival rates were compared by Kaplan-Meier 
analysis (  n   = 5).     JEM VOL. 205, September 29, 2008 
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  We performed BM transplantation (BMT) to test the 
functions of   Tsc1  -defi  cient HSCs. In serial BMT rescue 
experiments, we transplanted 10  6   WBM cells from either 
  Tsc1  fl / fl   mx-1-cre  +     or   Tsc1  fl / fl   mx-1-cre          mice without pIpC treat-
ment into lethally irradiated congenic CD45.1 recipients. Then 
we treated the recipients with pIpC every other day for 2 wk. 
After 12 more weeks, we killed the recipients and trans-
planted 3   ×   10  6   WBM cells from the recipients into a second 
group of lethally irradiated CD45.1 recipients. Stem-cell func-
tions were determined by testing the survival and hematopoi-
esis of the recipient mice, and donor-type cell reconstitution 
in the recipient peripheral blood at 6 wk after BMT (  Fig. 3 a  ).   
As shown in   Fig. 3 b  , although all second recipients of the 
Ctrl BMT survived, only fi  ve out of nine recipients of Tsc1-
defi  cient BM did, even though three times as many BM cells 
were used for the second BMT. Among the live secondary 
BMT recipients of the   Tsc1  -defi  cient BM, the majority of 
the CD45  +   cells were of the recipient type (  Fig. 3 c  ). Con-
sistent with a defective hematopoiesis of the   Tsc1  -defi  cient 
HSCs, the primary BMT recipients showed a drastic reduc-
tion in the white blood cells at 3 mo after completion of the 
pIpC treatments, with reduction in essentially all cell types 
analyzed, as measured by the CBC test (  Fig. 3 d  ). 
including that of granulocyte erythroid macrophage and mega-
karyocyte, and macrophage colonies was observed. The size of 
colonies from the KO BM was also actually somewhat larger 
(not depicted). In contrast, the percentage of cells undergoing 
apoptosis (Annexin V  +  7  –  aminoactinomycin D       ) was increased 
by almost fi  vefold in the KO BM (  Fig. 1 e  ). Therefore, the 
paradoxical BM hypocellularity in the KO mice is likely caused 
by apoptosis. In the spleen of   Tsc1   mutant mice, the B lympho-
cytes are reduced to half of those in Ctrl mice, whereas the 
erythroid cells are dramatically increased (  Fig. 2 d  ). 
  Interestingly, the numbers of megakaryocytes also increased 
(  Fig. 2 e  ), which suggested extramedullary hematopoiesis. 
Consistent with this notion, a signifi  cant numbers of HSCs was 
found in the   Tsc1  -defi  cient spleen but not in Ctrl spleen. The 
increase in the number of spleen HSCs persisted on day 30 after 
pIpC treatment, although this was decreased compared with 
that on day 10 (  Fig. 2 e  ). The HSCs in the Tsc1-defi  cient 
spleen rescued the lethally irradiated recipients for   >  9 mo (  Fig. 
2 f  ). However, because the HSCs have reduced self-renewal 
when their niche in BM is disrupted (  36  –  38  ), it is unlikely that 
the HSCs in the spleen are fully functional. Furthermore, the 
KO splenocytes gave rise to more CFUs, including granulocyte 
erythroid macrophage and megakaryocyte colonies (Table S1). 
    Figure 3.         The   Tsc1   deletion causes defective hematopoiesis.   (a  –  d) Serial BMT reveals HSC-intrinsic defects. (a) Diagram of experimental design 
for data in b  –  d. (b)   Tsc1- defi  cient BM cells are defective in rescuing lethally irradiated recipients in the second round, which indicate a reduced func-
tion of HSCs. 10  6   WBM cells were used for the fi  rst round of BMT, and 3   ×   10  6   WBM cells were used for the second round of BMT. According to   Fig. 1 f  , 
10  6   WBM cells from Tsc1-defi  cient mice contain     800 HSCs; those from Ctrl mice contain only     100 HSCs. For the WBM cells used for the second 
BMT, the frequency of HSCs was not analyzed. (c) Progressive loss of HSC activity as revealed by reduced replacement of recipient cells. Data shown 
are means   ±   SD of the percentage of donor cells in the blood of recipients at 6 wk after BMT (  n   = 15 for the fi  rst BMT, and   n   = 9 for the second 
BMT). (d) Reduced reconstitution of multiple lineages of blood cells by   Tsc1  fl  /fl   mx-1-cre +    BM. Data shown are means   ±   SD of the relative number of 
cells in the blood, as measured by CBC. Data are normalized as the percentage of mean counts in mice reconstituted with WT BM. Summary data 
from two independent experiments involving a total of nine mice per group are presented. LY, lymphocytes; MO, monocytes; NE, neutrophils 
and eosinophils.     2402   M  TOR AND STEMNESS OF HEMATOPOIETIC STEM CELLS   | Chen et al. 
the CD45.2  +   donor-type (either Ctrl or   Tsc1  fl / fl   mx-1-cre  +    ) and 
CD45.1 recipient-type WT BM were transplanted into le-
thally irradiated congenic CD45.1 recipients. The reconstitu-
tions in the recipient peripheral blood were analyzed at 4 and 
8 wk after BMT by fl  ow cytometry. As shown in   Fig. 4 b  , 
Ctrl BM cells contribute     30% in the peripheral blood of re-
cipients at 4 wk after BMT, whereas   Tsc1  -defi  cient BM cells 
only contribute   <  5% (P   <   0.0001). At 8 wk after BMT, the 
percentage of peripheral blood from the Ctrl donors further 
increased to     50%, whereas that from the mutant donors is 
reduced to   <  1%. Such reduction is evident among all of the 
lineages checked, including B cells, T cells, and myeloid cells. 
Thus, competitive BMT indicates that   Tsc1  -defi  cient HSCs 
have severely reduced function. 
  A potential caveat of this experiment is that the defects 
in the   Tsc1  -defi  cient HSCs can be caused by improper hom-
ing into the BM, as was observed in the   Pten  -defi  cient HSCs 
(  6, 25  ). To overcome this caveat, we mixed either the Ctrl 
or the   Tsc1  fl / fl   mx-1-cre  +     BM at a 1:1 ratio with recipient-type 
BM and transferred the cells into lethally irradiated mice. 
6 wk later, when the HSCs have properly homed and stably 
reconstituted the recipients, the recipients were treated with 
pIpC to delete the   Tsc1   gene in the   Tsc1  fl / fl   mx-1-cre  +     he-
matopoietic cells only (  Fig. 4 c  ). As shown in   Fig. 4 d  , at 
0 wk after completion of treatments, there was no signifi  -
cant diff  erence in the reconstitution rate by donor-type cells 
from   Tsc1  fl / fl   mx-1-cre  +     and   Tsc1  fl / fl   mx-1-cre          mice. At both 4 
and 8 wk after the treatments, we observed drastic reductions 
of   Tsc1  fl / fl   mx-1-cre  +     BM-derived leukocytes (CD45  +  ), particu-
larly in B cells (B220  +  ) and myeloid cells (Mac-1  +  ;   Fig. 4 d  ). 
Refl  ecting a slower turnover of the host T cell compartment, a 
gradual increase in the Ctrl T cells was observed after pIpC 
treatment. In contrast, neither an increase nor a reduction of T 
cells was observed at 4 and 8 wk after pIpC treatments in Tsc1-
defi  cient BMT. The lack of reduction is likely caused by slow 
turnover of the  Tsc1  fl / fl   mx-1-cre  +     T cells produced before the 
pIpC treatment. Collectively, these data clearly demonstrated 
that the HSC-intrinsic expression of   Tsc1   is essential for leuko-
genesis, and that the requirement of   Tsc1   is HSC intrinsic. 
  Functional rescue of HSC by rapamycin 
  Tsc1 is a known negative regulator for mTOR activity. To 
confi  rm the involvement of the mTOR pathway, we in-
jected the pIpC-treated   Tsc1  fl  /fl    mx-1-cre  +     and Ctrl mice with 
rapamycin (4 mg per kilogram of bodyweight) every other 
day starting at the fi  rst pIpC treatment and continuing through-
out the study. As shown in   Fig. 5 a  , the increase in the num-
ber of HSCs in both the BM and spleen of the pIpC-treated 
  Tsc1  fl / fl   mx-1-cre  +     mice was completely inhibited by rapamycin.   
The number of B cells, myeloid cells, and, to a lesser extent, 
erythroid cells in the BM were also restored (  Fig. 5 b  ). To 
confi  rm that rapamycin corrected the HSC-intrinsic, hom-
ing-independent defects, we repeated the BMT experiment 
depicted in   Fig. 4 c   and treated the mice with pIpC to delete 
  Tsc1   in the presence of rapamycin. As shown in   Fig. 5 c  , ra-
pamycin corrected the defects in all lineages of leukocytes. 
  A more accurate method to evaluate the function of HSCs 
is to compare them with WT BM cotransferred into the same 
recipients. We used this strategy in two diff  erent settings. 
First, as diagramed in   Fig. 4 a  , BM cells were isolated as soon 
as the pIpC treatments were completed.   The 1:1 mixtures of 
    Figure 4.         Cell-intrinsic requirement for TSC1 in the function of 
HSCs.   (a and b)   Tsc1 -defi  cient BM cells are dramatically less competent 
than WT BM cells in hematopoiesis when cotransferred into newly irradi-
ated hosts. (a) The experimental designs. (b) The percentage of donor-type 
cells within the indicated populations at 4 or 8 wk after transplantation. 
Note that although the percentage of WT BM-derived cells progressively 
increased, those from Tsc-defi  cient BM reduced to background levels within 
8 wk. Data shown are means   ±   SD (  n   = 5) and have been repeated twice. 
(c and d) Deletion of   Tsc1   after establishment of BMT reveals a cell-intrinsic 
and homing-independent role for Tsc1 in the function of HSCs. (c) Experi-
mental design. The   Tsc1  fl  /fl   MX-Cre +    or   Tsc1  fl  /fl   MX-Cre       BM were mixed at 
1:1 with recipient-type BM and transferred into irradiated recipients.   Tsc1  
deletion is induced at 6 wk after transplantation. (d) Means   ±   SD (  n   = 5) of 
the percentage of donor-type cells in the blood at 4 or 8 wk after comple-
tion of pIpC treatments. The experiments have been repeated three times.     JEM VOL. 205, September 29, 2008 
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  TSC1 maintains HSC function by repressing mitochondrion 
biogenesis and ROS production 
  As an essential integrator of multiple intrinsic and extrinsic 
signals, the TSC  –  mTOR pathway has been linked to many 
diff  erent downstream pathways, including protein synthe-
sis, autophagy, transcription, and mitochondrial metabolism 
(  21, 24  ). Because quiescent cells typically have reduced energy 
metabolism, we hypothesized that increased mitochondrion 
functions may epitomize the lack of quiescence observed af-
ter   Tsc1   deletion. We have produced several lines of evidence 
to substantiate this hypothesis. 
  First, we measured the mitochondrion mass by fl  ow cy-
tometry with MitoTracker Green, which emits fl  uorescence 
only after binding to the mitochondrial lipid membrane (  39  ). 
Our data demonstrated that   >  50% of the   Tsc1  -defi  cient HSCs 
had high mitochondrion contents, whereas   <  20% of the Ctrl 
HSC do (  Fig. 6 a  ).   By real-time PCR, we also found the 
number of mitochondrial DNA per HSC is almost doubled in 
pIpC-treated   Tsc1  fl / fl   mx-1-cre  +     mice compared with that in the 
Ctrl (  Fig. 6 b  ). Moreover, the transcripts of many mitochon-
drial genes that are involved in oxidative phosphorylation, 
including   Cyt C  ,   cox5a  ,   Ucp3  ,   Hdufs8  ,   Ind3  , and   Atp5a1  , are 
signifi  cantly up-regulated in   Tsc1  -defi  cient HSCs (  Fig. 6 c  ). 
  Second, mitochondrial oxidation may generate ROS. We 
therefore measured ROS levels in WT and Tsc1-defi  cient 
HSCs. 2  ’  ,7  ’  -dichlorodihydrofl  uorescein diacetate (DCF-DA) 
is an indicator of ROS levels because it is nonfl  uorescent 
until reacting with ROS inside the cells. In the Ctrl HSCs, 
ROS is repressed to very low levels. In contrast, the ROS 
level in the   Tsc1  -defi  cient HSCs was increased by approxi-
mately sevenfold, as indicated by fl  ow cytometry of DCF-DA 
staining (  Fig. 7 a  ).   
  ROS can be harmful to HSCs ( 26, 40 –  42  ). To test whether 
increased ROS is responsible for the lack of HSC function 
after   Tsc1   deletion, we used   N  -acetylcysteine (NAC), a widely 
used antioxidant, to scavenge free radicals. We treated the 
mice with NAC in drinking water combined with pIpC treat-
ment. 10 d after pIpC treatment, the ROS levels in   Tsc1  -
defi  cient HSCs were repressed by NAC treatment, whereas 
those in Ctrl HSCs remained essentially undetectable (  Fig. 7 b  ). 
The increases in both the frequency (  Fig. 7 c  ) and absolute 
number (  Fig. 7 d  ) of HSCs in the conditional   Tsc1  -defi  cient 
mice were largely abrogated by NAC treatment. Therefore, 
the increased ROS is likely an underlying cause for the in-
creased proliferation of HSCs. NAC treatment also prevented 
  Tsc1   deletion  –  induced BM hypocellularity (  Fig. 7 e  ). 
  To directly test the role of ROS in   Tsc1  -defi  cient HSCs, 
we performed competitive BMT, as diagramed in   Fig. 4 c  . 
The recipients were given NAC water in conjunction with 
pIpC treatments. At 4 and 8 wk after pIpC treatment, the re-
constitution rate of the total CD45.2  +   donor-type peripheral 
blood cells in NAC-treated   Tsc1  fl / fl   mx-1-cre  +     BM recipients 
was     45%, which is comparable to that of Ctrl BM. In con-
trast, the untreated   Tsc1  fl / fl   mx-1-cre  +     BM recipients have   <  10% 
of donor-type CD45  +   cells. This is refl  ected in the rescue of 
all major lineages (  Fig. 7 f  ). Therefore, NAC treatment, which 
These data demonstrated that the TSC  –  mTOR pathway plays 
an essential role in the maintenance and in vivo functions 
of HSCs. 
    Figure 5.         Hematopoietic functions of the Tsc1-defi  cient HSCs (cKO) 
are restored by rapamycin treatment.   (a) Rapamycin inhibited expansion 
of HSCs in the BM and in the spleen and restored normal hematopoiesis in 
the   Tsc1 -defi  cient BM. 6-wk-old   Tsc1  fl  /fl   MX-Cre +    (cKO) or   Tsc1  fl  /fl   MX-Cre      
(Ctrl) mice were treated with pIpC for 2 wk. At the same time, the mice were 
treated with either vehicle Ctrl of 4 mg/kg rapamycin every other day 
throughout the entire period of the study. The HSC numbers shown were 
LSK cells at day 10 after completion of pIpC treatment. Similar restorations 
were observed on day 30. At both time points, the numbers of LT-HSCs were 
also reduced to normal levels (not depicted). (b) Rapamycin restores he-
matopoiesis in   Tsc1- defi  cient BM. The data are the number of different 
lineages of cells from the BM collected at 30 d after pIpC treatments. Data 
shown were means   ±   SD (  n   = 4) from two independent experiments. 
(c) Rapamycin abrogates HSC-intrinsic functional defects caused by the 
deletion of   Tsc1  . The chimeric mice described in   Fig. 4 c   were treated with 
rapamycin, starting at the time of the pIpC treatment (4 mg/kg every other 
day, throughout the study). At 8 wk after completion of pIpC treatment, the 
mice were killed, and total and specifi  c lineages of hematopoietic cells were 
analyzed by fl  ow cytometry. Data shown are means   ±   SD of the percentage 
of cells of donor origin from two independent experiments (  n   = 10).    2404   M  TOR AND STEMNESS OF HEMATOPOIETIC STEM CELLS   | Chen et al. 
the adult mice. Recent studies have demonstrated that this 
approach leads to a nearly complete deletion of genes in the 
HSCs (  6, 25  ), as we have demonstrated in the case of   Tsc1.   
Using pS6 protein as a marker for mTOR activation, our 
data demonstrated a dramatic elevation of mTOR activity in 
the HSCs after the   Tsc1   deletion. 
  In conjunction with mTOR activation, we observed a 
massive increase in HSC proliferation, RNA synthesis, mito-
chondrial biogenesis, and the production of ROS. Although it 
has been well established that adult HSCs divide slowly (  1  –  6  ), 
the pathway that keeps them in the G0 phase has been largely 
unclear. Our data demonstrate that the TSC  –  mTOR path-
way plays an essential role in keeping HSC in G0 phase. In-
creased proliferation of the HSCs has also been observed after 
a targeted mutation of the   Pten   gene in the HSCs (  6, 25  ). Be-
cause Pten is a negative regulator of the PI3K  –  AKT pathway, 
which in turn stimulates mTOR by inactivating the TSC 
complex (  31, 32  ), it is likely that the inactivation of TSC1 is 
inhibited ROS in   Tsc1  -defi  cient HSCs, restored the HSC in 
vivo functions. These data strongly indicate that ROS is a 
major target of the TSC  –  mTOR pathway in HSCs. 
    DISCUSSION   
  The mTOR pathway has emerged as a central regulator for 
cellular growth, diff  erentiation, and energy response (  21  ). How-
ever, despite the extensive use of the mTOR inhibitors for im-
mune suppression, the function of mTOR in the hematopoietic 
system has not been analyzed genetically. In this paper, we showed 
that the targeted mutation of   Tsc1  , an essential and specifi  c nega-
tive regulator of mTOR complex 1 (  31, 32  ) (for review see refer-
ence   33  ), abrogated the quiescence and function of HSCs. 
  Tsc1 as an essential negative regulator for the quiescence 
of HSCs 
  Because germline mutations of   Tsc1   are embryonically lethal, 
we used the   MX1-Cre   transgene to induce deletion of   Tsc1   in 
    Figure 6.         Up-regulated mitochondrial biogenesis in   Tsc1-  defi  cient, FLSKCD48            HSCs.   (a)   Tsc1   deletion results in increased mitochondrial biogen-
esis, as revealed by increased MitoTracker Green  –  high populations. (left) A representative FACS profi  le from one mouse BM LT-HSC is shown (numbers 
indicate percentages). (right) The summary data (means   ±   SD;   n   = 4) of the percentage of cells with high mitochondrion contents are shown. (b) Relative 
mitochondrion DNA contents in WT and Tsc1-defi  cient LT-HSCs. Mitochondrial DNA and genomic DNA were extracted from HSCs, and the copy number of 
mitochondrial DNA was measured by RT-PCR, normalized to genomic DNA. As a Ctrl, the mitochondrial DNA copy numbers from the tails of the Ctrl and 
mutant mice are measured. The mean abundance in Ctrl HSCs was defi  ned as 1. Data shown are means   ±   SD (  n   = 3). (c) Up-regulation of the expressions 
of mitochondrial genes involved in oxidative phosphorylation in   Tsc1 -defi  cient HSCs. The mRNA levels of mitochondrial genes (  Cyt C ,  Cox5a ,  UCP3 ,  Hdufs8 ,  
Idh3a  , and   Atp5g1  ) are measured by real-time RT-PCR. Data shown were means   ±   SD of the fraction of Hprt copy numbers (  n   = 4). The data presented in 
this fi  gure have been reproduced in at least four experiments.     JEM VOL. 205, September 29, 2008 
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  Tsc1      /        HSCs actually had slightly higher levels of p21 tran-
script (unpublished data), a lack of quiescence of   Tsc1      /        
HSCs cannot be caused by a reduction in   p21   expression. 
at least in part responsible for Pten-induced hyperproliferation 
of HSCs. On the other hand, a targeted mutation of   p21   is also 
known to induce hyperproliferation of HSCs (  5  ). Because the 
    Figure 7.         Tsc1 maintains the function of HSCs by repressing the production of ROS.   (a) The   Tsc1 -defi  cient HSCs show dramatically increased 
levels of ROS, as indicated by DCF-DA staining. (left) Data shown are overlays of a FACS profi  le. (right) Data shown are means   ±   SD (  n   = 5) of the 
change in mean fl  uorescence after subtracting autofl  uorescences of HSCs. (b) ROS antagonist (NAC) treatment reduces the ROS level in Tsc1 mutant 
HSCs. Ctrl and   Tsc1 -defi  cient mice were treated with 1 mg/ml NAC in their drinking water in conjunction with pIpC treatment and were killed 10 d 
after the last pIpC injection. The BM cells were stained with HSC markers (FLSK) in conjunction with the ROS sensing dye DCF-DA. Data shown are 
relative levels of ROS. The mean fl  uorescence of untreated Ctrl HSCs is artifi  cially defi  ned as 1. Data shown are means   ±   SD (  n   = 4). (c) The BM cel-
lularity in Tsc1 mutant mice is signifi  cantly rescued by NAC treatment. The BM cells used were as described in b. Data shown are means   ±   SD (  n   = 4). 
(d and e) The HSC frequency (d) and absolute number (e) in   Tsc1   mutant mice were reduced to normal levels by NAC treatment. Results are as in b 
and c, except that the percentages and numbers of FLSK HSCs were analyzed. (f) In stable BM chimera consisting of WT and TSC    fl  /fl      BM cells, the re-
constitution capacity of Tsc1-defi  cient HSCs is signifi  cantly rescued by NAC treatment. Chimera mice depicted in   Fig. 4 c   were treated with NAC in 
their drinking water, starting at the same time of pIpC treatment. Blood samples were collected at the indicated time points and were analyzed by 
fl  ow cytometry for the percentage of CD45.2  +   donor cell types, B220  +   B cells, and CD11b  +   myeloid cells of donor type. Data shown are means   ±   SD 
from two independent experiments (  n   = 10).     2406   M  TOR AND STEMNESS OF HEMATOPOIETIC STEM CELLS   | Chen et al. 
with active metabolism. Therefore, our study provides a novel 
explanation on why HSCs must remain quiescent to main-
tain their   “  stemness.  ”   
  Because the mTOR pathway is regulated by glucose, nu-
trients, and O  2   levels (  21  ), it would be of great interest to 
determine whether abnormal mTOR activation is the un-
derlying cause for the loss of quiescence in HSCs after disrup-
tion of the stem cell niche in vivo (  36  –  38  ). In toto, our data 
suggest mTOR activation as a unifying explanation of the re-
quirements of HSC niche and quiescence in HSC function. 
  MATERIALS AND METHODS 
  Mice.     Tsc1  fl  /fl     mice (  49  ) were provided by D.J. Kwiatkowski (Brigham and 
Women  ’  s Hospital, Boston, MA) and were backcrossed for six generations 
onto the C57BL/6 background in the animal facility at the University of 
Michigan. Mx-1-cre mice were purchased from the Jackson Laboratory 
(  50  ). Recipients in reconstitution assays were 8-wk-old B6ly5.2 mice from 
the National Cancer Institute. All procedures involving experimental ani-
mals were approved by the University Committee on the Use and Care of 
Animals at the University of Michigan. 
  pIpC, rapamycin, and NAC treatment.     pIpC (Sigma-Aldrich) was re-
suspended in PBS at 1 mg/ml. Mice received 15 mg/kg of pIpC every other 
day seven times by i.p. injection (  51  ). Rapamycin (Sigma-Aldrich) was re-
constituted in absolute ethanol at 10 mg/ml and diluted in 5% Tween-80 
(Sigma-Aldrich) and 5% PEG-400 (Hampton Research). Mice received 4 mg/kg 
rapamycin by i.p. injection every other day. NAC (Sigma-Aldrich) was 
delivered through feeding water at 1 mg/ml. 
  Flow cytometry.     BM cells were fl  ushed by a 25-gauge needle from the 
long bones (tibias and femurs) with HBSS without calcium or magnesium 
(Invitrogen), supplemented with 2% heat-inactivated fetal bovine serum. 
Peripheral blood was obtained from the tail veins of recipients at the time 
points indicated in the fi  gures, and RBCs were lysed by ammonium chloride/
potassium bicarbonate buff  er before staining. 
  For fl  ow cytometry and purifi  cation of HSCs, the FLSKCD48        pheno-
type is used for LT-HSCs, and the Lin       Sca-1  +  c-kit  +  CD48  +   phenotype is 
used for short-term HSCs (  34  ). Lineage markers included B220, CD3, Gr-1, 
Mac-1, and Ter119 (BD Biosciences). Flow cytometry analysis was performed 
on an LSR II (BD Biosciences), and FACS was performed on a FACSAria 
(BD Biosciences). All other antibodies were obtained from eBioscience. 
  For pS6 staining, BM cells were stained with the surface markers and 
fi  xed with fi  x/permealization buff  er (BD Biosciences), and then incubated 
with Alexa Fluor 488  –  conjugated pS6 antibodies (Cell Signaling Technol-
ogy) for 2 h in ice. The samples were analyzed by fl  ow cytometry after the 
removal of unbound antibodies. 
  To determine the RNA/DNA content, fresh BM cells were stained 
with surface markers for HSCs and fi  xed in cold 70% ethanol overnight at 
    20  °  C. 4   μ  g/ml pyronin Y (Sigma-Aldrich) and 2   μ  g/ml HOECHST 33342 
(Sigma-Aldrich) were stained for 30 min at 4  °  C. 
  BrdU (BD Biosciences) was injected i.p. into adults at 100 mg/kg. The 
mice were then given 1 mg/ml BrdU water for 24 h and killed for analysis. 
BrdU staining was performed according to the producer  ’  s manual. 
  MitoTracker Green (Invitrogen) was stained at 50 nM for 15 min at 
37  °  C after staining of surface markers. ROS was measured by DCF-DA 
(Invitrogen) staining at 10   μ  M for 15 min at 37  °  C after staining of surface 
markers, according to the manufacturer  ’  s manual. 
  BMT.     8-wk-old recipient mice were lethally irradiated with a Cs-137 x-ray 
source delivering 180 rads per min, for a combined 1,100 rads, delivered 
  >  2 h apart. Donor WBM cells with or without competitive recipient-type 
WBM cells were transplanted into recipients through the retroorbital ve-
nous sinus 24 h after irradiation. Reconstitutions were measured by fl  ow 
  Overactivation of mTOR alone is insuffi  cient to cause 
hematological malignancies in the mice 
  Part of the phenotypes we presented in this paper, including 
the increased proliferation and lost functions, are consistent 
with those reported in the   Pten  -defi  cient HSCs (  6, 25  ). Thus, 
even though it has been argued that the PI3K  –  Akt path-
way regulates the HSCs mainly through FOXOs instead of 
mTOR (  40  ), our data are consistent with the notion that in 
HSCs,   Pten   is also an upstream regulator of the TSC  –  mTOR 
pathway, as revealed in other models (  33  ). However, there 
are signifi  cant diff  erences between   Tsc1  -defi  cient HSCs and 
  Pten  -defi  cient HSCs. Although   Pten   deletion promotes severe 
myeloproliferative disease within days (  6, 25  ), we did not ob-
serve leukemia or other malignancies in mice with   Tsc1   dele-
tion in HSCs. Nor did we observe a single case of leukemia 
in BMT recipients when the   Tsc1-  defi  cient BM was serially 
transplanted over a 1-yr period after   Tsc1   deletion. Flow cy-
tometry analysis also found no myeloid dysplasia, as reported 
in mice with a conditional deletion of the   Pten   gene (unpub-
lished data). The inability of   Tsc1   mutation to cause cancer is 
supported by a general lack of cancer among TSC patients 
(  33  ). However, our data did not rule out the possibility that 
  Tsc1   deletion can provide one of several genetic changes nec-
essary for tumorigenesis in the   Pten  -defi  cient BM. 
  It should be noted that the Pten protein resides in distinct 
cellular pools and can mediate functions other than regulating 
the TSC  –  mTOR pathway (  43  –  45  ). In addition, because of 
the feedback of S6 kinase to insulin receptor substrate 1, Akt 
is activated by   Pten   deletion but inhibited in   Tsc   mutants (  46  ). 
The transformation of HSCs by   Pten   deletion might also be 
explained by the nuclear functions of Pten to maintain chro-
mosomal integrity and/or activation of Akt (  44  ). It remains 
to be investigated which pathway explains the diff  erence in 
phenotypes after the deletion of   Pten   versus   Tsc1  . 
  An explanation for the requirement of stem cell niches and 
quiescence for maintaining the long-term function of HSCs 
  Notably, previous studies on the quiescence of HSCs have 
been limited to cell-cycle regulation. Hyperproliferation by 
itself, however, does not necessarily inhibit stem cell func-
tion, as fetal HSCs do divide at a high rate (  47  ). Our data 
provide a missing link between the   Tsc    –  mTOR pathway and 
mitochondrial biogenesis, and up-regulation of genes in-
volved in oxidative function in the HSCs. Perhaps because of 
unbalanced production and removal, ROS levels increased 
dramatically in the   Tsc1-  defi  cient HSCs, which we show to 
be responsible for defects in HSC function. Recently, Suzuki 
et al. (  48  ) reported a very modest increase (7% over Ctrl) of 
ROS activity when   Tsc2   mutants were ectopically expressed 
in COS cells, and argued that this gain of function relates to 
Rac activation but is independent of   Tsc1   loss and is, there-
fore, presumably independent of mTOR activation. It re-
mains to be tested whether the pathway uncovered in our 
study is unique for HSCs. 
  Because the HSCs are highly sensitive to ROS (  26, 40  –  42  ), 
they are not programmed to neutralize products associated JEM VOL. 205, September 29, 2008 
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